Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients – A cohort study

Table 2 Annual incidences of clinical outcomes of patients with renal function of 30 ≤ CrCl < 60 mL/min, 60 ≤ CrCl < 90 mL/min and CrCl ≥ 90 mL/min

Variables	Warfarin	DOAC				P value (Warfarin vs. DOAC)	P value
Variables		Dabigatran	Rivaroxaban	Apixaban	Edoxaban	P value (Warfarin vs. DOAC)	(4 DOACs)
*30 ≤ CrCl < 60 mL/min*
Thromboembolic events (%)	1.22	0.72	1.01	1.41	1.29	0.30	0.22
Major and fatal bleeding (%)	0.94	0.56	0.76	0.74	0.43	0.51	0.69
GI bleeding (%)	1.46	0.87	1.29	1.67	0.86	0.18	0.14
Intracranial hemorrhage (%)	0.63	0.21	0.48	0.33	0.29	0.22	0.42
*60 ≤ CrCl < 90 mL/min*
Thromboembolic events (%)	0.57	0.57	0.90	0.78	0.75	0.62	0.68
Major and fatal bleeding (%)	0.37	0.34	0.25	0.29	0.19	0.92	0.93
GI bleeding (%)	0.53	0.52	0.58	0.87	0.56	0.78	0.68
Intracranial hemorrhage (%)	0.49	0.34	0.36	0.10	0.19	0.45	0.54
*CrCl ≥ 90 mL/min*
Thromboembolic events (%)	0.81	1.40	0.38	0.86	1.09	0.24	0.09
Major and fatal bleeding (%)	0.32	0	0.19	0.29	0	0.60	0.45
GI bleeding (%)	0.57	0.16	0.66	0.57	0	0.52	0.41
Intracranial hemorrhage (%)	0.57	0	0.19	0.29	0	0.19	0.45

Abbreviation: CrCl: creatinine clearance; DOAC: direct oral anticoagulant; GI: gastrointestinal

ISSN: 1477-9560